Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
AstraZeneca
Medtronic
QuintilesIMS
Novartis
Argus Health
Colorcon
Teva
Covington
Dow

Generated: October 23, 2017

DrugPatentWatch Database Preview

VARUBI Drug Profile

« Back to Dashboard

What is the patent landscape for Varubi, and when can generic versions of Varubi launch?

Varubi is a drug marketed by Tesaro Inc and is included in one NDA. There are eight patents protecting this drug.

This drug has one hundred and twenty-three patent family members in thirty-two countries.

The generic ingredient in VARUBI is rolapitant hydrochloride. One supplier is listed for this compound. Additional details are available on the rolapitant hydrochloride profile page.

Summary for Tradename: VARUBI

US Patents:8
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list12
Clinical Trials: see list4
Patent Applications: see list30
Drug Prices:see details
DailyMed Link:VARUBI at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Tesaro Inc
VARUBI
rolapitant hydrochloride
TABLET;ORAL206500-001Sep 1, 2015RXYesYes► Subscribe► Subscribe ► Subscribe
Tesaro Inc
VARUBI
rolapitant hydrochloride
TABLET;ORAL206500-001Sep 1, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Tesaro Inc
VARUBI
rolapitant hydrochloride
TABLET;ORAL206500-001Sep 1, 2015RXYesYes► Subscribe► Subscribe ► Subscribe
Tesaro Inc
VARUBI
rolapitant hydrochloride
TABLET;ORAL206500-001Sep 1, 2015RXYesYes► Subscribe► SubscribeYY ► Subscribe
Tesaro Inc
VARUBI
rolapitant hydrochloride
TABLET;ORAL206500-001Sep 1, 2015RXYesYes► Subscribe► Subscribe ► Subscribe
Tesaro Inc
VARUBI
rolapitant hydrochloride
TABLET;ORAL206500-001Sep 1, 2015RXYesYes► Subscribe► SubscribeYY ► Subscribe
Tesaro Inc
VARUBI
rolapitant hydrochloride
TABLET;ORAL206500-001Sep 1, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Tesaro Inc
VARUBI
rolapitant hydrochloride
TABLET;ORAL206500-001Sep 1, 2015RXYesYes► Subscribe► Subscribe ► Subscribe
Tesaro Inc
VARUBI
rolapitant hydrochloride
TABLET;ORAL206500-001Sep 1, 2015RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: VARUBI

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,902,366NK.sub.1 antagonists► Subscribe
9,688,693NK.sub.1 antagonists► Subscribe
8,273,895NK.sub.1 antagonists► Subscribe
9,345,692Pharmaceutical formulations: salts of 8-[1-3,5-bis-(trifluoromethyl)phenyl)-ethoxy-methyl]-8-phenyl-1,7-diaza-s- piro[4.5]decan-2-one and treatment methods using the same► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: VARUBI

Country Document Number Estimated Expiration
Peru05452012► Subscribe
Japan5823476► Subscribe
China101437821► Subscribe
Chile2008000819► Subscribe
Norway20084660► Subscribe
Spain2406934► Subscribe
Hong Kong1065036► Subscribe
Brazil0215158► Subscribe
Japan2013049720► Subscribe
Japan2015108023► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Chubb
Healthtrust
Daiichi Sankyo
McKinsey
Express Scripts
Cantor Fitzgerald
Johnson and Johnson
Baxter
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot